All News

Muscle (keep)

Immune Necrotizing Myopathy

Jack Cush, MD

A full read review of immune-mediated necrotizing myopathy is portrayed as a distinct subtype of inflammatory myopathies first described in 2004.

Read Article
Covid lung pneumonia corona (keep)

Clinical Trial Boom or Bust in Severe COVID-19

Jack Cush, MD

A number of recently published clinical trials are further defining the efficacy and outcomes of tocilizumab or remdesivir in treating SARs-CoV-2 infection.



Remdesivir

Read Article
vasculitis.Churg-Strauss_syndrome.wikipedia.jpg

Biologics Beneficial in Eosinophilic Vasculitis

Two biologic therapies showed promise in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (EGPA) in a retrospective European study.

Read Article
GPA.jpg

Sustained Remission Off Therapy Unlikely in GPA

Jack Cush, MD

A French Vasculitis Study Group analysis of their granulomatosis with polyangiitis (GPA) reveals that after 10 years, only 7% of GPA patients achieved sustained remission off therapy (SROT) and have never relapsed.

Read Article
steroids.prednisone.pills_.jpg

Systemic Steroids Reduce Mortality in COVID-19

Jack Cush, MD

JAMA Internal Medicine reports an analysis of COVID-19 clinical trials showing that critically ill patients with COVID-19 treated with systemic corticosteroids have an overall lower mortality rate.

Read Article
podcast logo

RheumNow Podcast – Cardiovascular Risk in Psoriatic Disease (9.25.20)

Jack Cush, MD

Dr. Jack Cush reviews the news and Journal articles from the past week on RheumNow.com.

Read Article
guidelines.recommendations.jpg

EULAR Updated 2019 Recommendations for Psoriatic Arthritis Management

Jack Cush, MD

In June 2020, we failed to report on the ARD publication updating the 2019 update the European League Against Rheumatism (EULAR) recommendations for the pharmacological treatment of psoriatic arthritis (PsA) - these are presented below.

Read Article
Summary of #ACR20 part B: - The future is bright with many trainees producing great research per Dr. Diane Karen - Belimumab (phase III) reduced proteinuria, improved renal for, and helped w/ tapering of GC in pts w/ lupus nephritis but more infect in GC group @RheumNow

Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)

2020 #ACR20 RA guidelines were against steroid usage in RA. ESPOIR French cohort: 10 years of very low dose GC show increase events (death/CVD/fracture/severe ifn) even on low doses. HR increases every year. Cum GC dose-effect esp ifn, CVD. @RheumNow #ACRBest https://t.co/7b7chCPRxm
Eric Dein ejdein1 ( View Tweet)
When you give IA steroids for knee OA how long do you tell pts it will work for @RheumNow #ACR20 @CRASCRRheum abstr#1650

Janet Pope Janetbirdope ( View Tweet)

Intra-articulations steroids for the knee OA- finding benefits again! IA steroids were good then villified in press with accelerated cartilage loss. Pendulum swings back in abstr#1649 where quadriceps & gait improve post injection @RheumNow #ACR20 @CRASCRRheum #ACRbest https://t.co/0bRsiEKsW4
Janet Pope Janetbirdope ( View Tweet)
Study of Chinese pts on long-term GCs by Dr CC Mok: DEN >> ALN in ⬆spinal BMD & suppressing bone turnover markers after 1yr tx. No sig. diff in AEs among grps. Limits: Open-label,small ss,short tx dur'n, not powered for fractures @RheumNow #ACR20 abs1442 https://t.co/m8mT0hMPN8
sheila RHEUMarampa ( View Tweet)
Dr. M. “Peggy” Crow’s #StateofArt lecture at #ACR20 reminds us that HCQ is the foundation of tx, to keep prednisone goal < 7.5mg/d, and that BEL works best in early dz (< 2 yrs) Summary slide provided. https://t.co/3LbWqwwOsr
Dr. Rachel Tate uptoTate ( View Tweet)
Ground-breaking news... the end of #glucocorticoid use in #AAV? very exciting to reduce GC toxicity! https://t.co/43eCofpOIX
KenWarringtonMD MdWarrington ( View Tweet)
#ACR20 year in review by @JYazdanyMD latest data PEXIVAS and SEMIRA trials on corticosteroids - would you change your clinical practice to minimize even low dose Corticosteroids in RA and Vasculitis? @RheumNow https://t.co/l7PTyANpjq https://t.co/MRGbsjaGae

Links:

Bella Mehta bella_mehta ( View Tweet)

Reminder of the glucocorticoids (GC) paradigm: don’t use them early during viral replication as morbidity and mortality (M&M) can increase with early use! But GCs CAN prevent the late complications that cause M&M when used at the appropriate time point. #ACR20 @RheumNow https://t.co/l2e0J1nANd
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
#ACR20 Year in Review @JYazdanyMD presenting PEXIVAS results. The proof of efficacy equivalence and safety superiority for the low dose steroid arm is a game-changer @rheumnow https://t.co/bJ1WLL71sB
Richard Conway RichardPAConway ( View Tweet)
"Prednisone >30 mg/day for > 4 weeks, patients should be on PJP prophylaxis." Image shows when to start/stop PJP prophylaxis Dr. Kevin Winthrop on Risks/Prevention of OI @UTSWRheum Grand Rounds @rheumnow https://t.co/nXuWYRxbgy
k dao KDAO2011 ( View Tweet)
14203 early RA cohort looked at adherence to quality standards of care (DMARD use, steroids, early F/U care) and showed adherence lessened need for future hospitalisation (adj HR 0.85); most impact from early DMARDs, worst from steroid use https://t.co/hzICGWyht2

Links:

Dr. John Cush RheumNow ( View Tweet)

Ann Int Med shows again that steroids increase serious infection risk in a dose dependenet manner, but even 5 mg of prednisone or less also gives a small but significant risk of serious infection in RA patients on DMARDs (claims data from Medicare & Optum) https://t.co/bj41SqKP0K

Links:

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×